It is difficult for physicians to estimate recurrence and survival in patients with esophageal cancer. Researchers have found that the response of lymph nodes, as opposed to that of primary tumors, to neoadjuvant chemotherapy is more effective in predicting disease recurrence and patient survival in individuals with metastatic esophageal cancer. This finding is likely to enhance the accuracy of predictions regarding treatment outcome, and may lead to improved treatment approaches.